340B Health president was a recent guest on Monitor Monday. The following are edited remarks of her presentation.
2019 was another very busy year for people involved in the 340B drug pricing program. And it marked the end of a remarkable decade of progress and challenges.
One of the most important developments of this past year was the creation of a new, secure website for use by 340B covered entities to check the ceiling prices that they should be charged for all drugs covered by 340B. This is the first time such a resource has been available, and it introduced some much-needed price transparency. We are already seeing evidence of this working well. More than a dozen pharmaceutical companies have had to revise their pricing, and in many cases, pay refunds to hospitals, health centers, and clinics that had been charged too much. The Health Resources and Services Administration deserves tremendous credit for the creation of this valuable website tool.
We also saw the beginning of a national debate over drug pricing. President Trump and the leaders of both political parties on Capitol Hill have put some important ideas on the table for debate. While there are many differences in how they approach this issue, the key point is that patients need relief from the high cost of prescription drugs, and so do the safety-net providers that care for them. It is my hope that in 2020, our leaders can come together on a common-sense set of reforms that slow the rise in prices, protect patients from financial pain, and protect the vital safety net.
We also saw a continuation of the fight over how much Medicare pays 340B hospitals for drugs. Beginning in 2018, Medicare has been paying these hospitals nearly 30 percent less than it pays all other hospitals. A lawsuit challenging those cuts has led to a federal court ruling them to be unlawful. But the government is appealing that decision, and the cuts remain in place for now. These cuts are harming hospitals and their patients, and the sooner they are ended, the better. We must see a resolution to this issue early in 2020 so that we can get things back on an even keel.
I’d also like to call attention to a very important initiative that President Trump announced nearly one year ago in his State of the Union address to Congress. The President called for dramatic action to reduce the number of infections with the human immunodeficiency virus (HIV) that causes AIDS. In fact, the President set an ambitious goal to reduce infections by 90 percent by the end of the new decade.
To achieve this, we must make sure that people who are at risk of acquiring HIV have access to prevention treatment, known as PrEP, that reduces their risk by more than 90 percent. And we must make sure people living with HIV have access to treatment that provides longer lives and reduced risk. A key part of that effort is the lower prices for these drugs that 340B guarantees.
Finally, I will note that states have grown more active in 340B policymaking. In previous years, states focused primarily on how much their Medicaid programs were paying for drugs covered by 340B. But in 2019, we saw several states adopt legislation putting limits on private payors so that they cannot set discriminatory payment levels for 340B hospitals and pharmacies. This is an important issue for 340B. Paying 340B providers less just because they are in 340B undermines the purpose of the program because it transfers the benefits from safety-net providers to insurers who are not in the business of treating low-income patients. State action to prevent this from happening is definitely a move in the right direction. I expect states will remain active in 2020 on 340B-related issues.
We start this new year and new decade with cautious optimism. It’s easy to focus on what divides us, but at this point in our national debate over healthcare, it will serve us well to focus on what can bring us together.
We have been talking a lot lately about the malfeasance of Medicare Advantage (MA) plans, and deservedly so. But malfeasance can be a two-way street.
While President-elect Trump’s pick for U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy, Jr., put the agency in even international newspapers
Please log in to your account to comment on this article.
Join Beth Wolf, MD, CPC, CCDS, for an in-depth webcast on the FY2025 spinal fusion MS-DRG updates. Discover key changes in DRG classification, understand impacts on documentation and CMI, and learn strategies to ensure compliance.
Join Angela Comfort, DBA, MBA, RHIA, CDIP, CCS, CCS-P, as she presents effective strategies to strengthen collaboration between CDI, coding, and quality departments in acute care hospitals. Angela will also share guidance on implementing cross-departmental meetings, using shared KPIs, and engaging leadership to foster a culture of collaboration. Attendees will gain actionable tools to optimize documentation accuracy, elevate quality metrics, and drive a unified approach to healthcare goals, ultimately enhancing both patient outcomes and organizational performance.
Optimize your outpatient clinical documentation and gain comprehensive knowledge from foundational practices to advanced technologies, ensuring improved patient care and organizational and financial success. This webcast bundle provides a holistic approach to outpatient CDI, empowering you to implement best practices from the ground up and leverage advanced strategies for superior results. You will gain actionable insights to improve documentation quality, patient care, compliance, and financial outcomes.
Enhancing outpatient clinical documentation is crucial for maintaining accuracy, compliance, and proper reimbursement in today’s complex healthcare environment. This webcast, presented by industry expert Angela Comfort, DBA, RHIA, CDIP, CCS, CCS-P, will provide you with actionable strategies to tackle complex challenges in outpatient documentation. You’ll learn how to craft detailed clinical narratives, utilize advanced EHR features, and implement accurate risk adjustment and HCC coding. The session also covers essential regulatory updates to keep your documentation practices compliant. Join us to gain the tools you need to improve documentation quality, support better patient care, and ensure financial integrity.
Dr. Ronald Hirsch provides critical details on the new Medicare Appeal Process for Status Changes for patients whose status changes during their hospital stay. He also delves into other scenarios of hospital patients receiving custodial care or medically unnecessary services where patient notifications may be needed along with the processes necessary to ensure compliance with state and federal guidance.
Healthcare organizations face complex regulatory requirements under the No Surprises Act and Price Transparency rules. These policies mandate extensive fee disclosures across settings, and confusion is widespread—many hospitals remain unaware they must post every contracted rate. Non-compliance could lead to costly penalties, financial loss, and legal risks. Join David M. Glaser Esq. as he shows you how to navigate these regulations effectively.
Protect your facility from unwanted audits! Join Becky Jacobsen, BSN, RN, MBS, CCS-P, CPC, CPEDC, CBCS, CEMC, and take a deep dive into both the CMS and AMA guidelines for reporting post operative pain blocks. You’ll learn how to determine if the nerve block is separately codable with real life examples for better understanding. Becky will also cover how to evaluate whether documentation supports medical necessity, offer recommendations for stronger documentation practices, and provide guidance on educating providers about documentation requirements. She’ll include a discussion of appropriate modifier and diagnosis coding assignment so that you can be confident that your billing of post operative pain blocks is fully supported and compliant.
During this RACmonitor webcast Dr. Ronald Hirsch spotlights the areas of the OIG’s Work Plan and the findings of their most recent audits that impact utilization review, case management, and audit staff. He also provides his common-sense interpretation of the prevailing regulations related to those target issues. You’ll walk away better equipped with strategies to put in place immediately to reduce your risk of paybacks, increased scrutiny, and criminal penalties.
Copyright © 2024 RACmonitor. Powered by MedLearn Media.
Happy National Doctor’s Day! Learn how to get a complimentary webcast on ‘Decoding Social Admissions’ as a token of our heartfelt appreciation! Click here to learn more →
